REG - Verici Dx PLC - Result of Annual General Meeting

Verici DxAnnouncement

30/07/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250730:nRSd0851Ta&default-theme=true

RNS Number : 0851T  Verici Dx PLC  30 July 2025

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Result of Annual General Meeting

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that at the Annual General Meeting ("AGM") held
yesterday, all resolutions were duly passed.

 

The voting results of the AGM were as follows:

 

             In Favour            Against        Withheld
 Resolution  Votes        %       Votes    %     Votes
 1           469,065,903  99.98   88,290   0.02  24,006
 2           468,421,915  99.85   718,633  0.15  37,651
 3           469,047,227  99.98   106,783  0.02  24,189
 4           469,057,547  100.00  21,408   0.00  99,244
 5           468,889,463  99.96   189,044  0.04  99,692

 

 

 Verici Dx plc                                       www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                                Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker and Joint Bookrunner)                Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Oberon Capital (Joint Broker and Joint Bookrunner)  Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock / Jessica Cave

 Walbrook PR (Media & Investor Relations)            Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Paul McManus                       Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBKLLLEDLEBBE